Characteristics of extracellular cyclic AMP‐dependent protein kinase as a biomarker of cancer in dogs. (9th February 2017)

• Record Type: Journal Article
• Authors: Bhang, D. H.; Choi, U. S.; Kim, B. G.; Lee, S.‐N.; Lee, S.; Roh, H.‐S.; Chung, W.‐J.; Jeon, K. O.; Song, W. J.; Youn, H.‐Y.; Baek, K.‐H.
• Is Part Of: Veterinary and comparative oncology. Volume 15:Number 4(2017:Dec.)
• Page Start: 1585
• Page End: 1589
• Publication Date: 2017-02-09
• Subjects: cancer biomarker -- dog -- enzyme‐linked immunosorbent assay -- extracellular protein kinase A -- serum; Veterinary oncology -- Periodicals; Neoplasms -- veterinary -- Periodicals; 636.0896994005
• DOI: 10.1111/vco.12304
• Languages: English
• ISSNs: 1476-5810

Abstract

Abstract : Objective: Early and proper diagnosis of cancer is the most critical factor for the survival and treatment of veterinary cancer patients. In this study, we evaluated extracellular cyclic AMP‐dependent protein kinase A (ECPKA) level in serum as a useful cancer biomarker in dogs. Methods: ECPKA levels were detected in sera from dogs with cancers ( n = 48), benign tumours ( n = 18), and non‐tumour diseases ( n = 102) as well as healthy control dogs ( n = 54) utilizing enzyme‐linked immunosorbent assay (ELISA). Results: Sera from dogs bearing various types of cancer exhibited markedly increased levels of ECPKA by up to 7.1‐, 8.8‐, and 10.9‐fold compared with those from dogs harbouring benign tumours, dogs with non‐tumour diseases, and healthy control dogs, respectively ( P < .0001). In addition, serum ECPKA level did not show statistically significant correlation with gender, breed, or age of dogs or their non‐cancerous disease conditions. Conclusion: Our data strongly propose that detection of serum ECPKA level is a potential and specific diagnostic tool for cancer in dogs.